BRIEF-Sage Therapeutics reports top-line results from Phase 3 STATUS trial of brexanolone [Reuters]
Sage Therapeutics, Inc. (SAGE)
Last sage therapeutics, inc. earnings: 2/27 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.sagerx.com/investor-relations
Company Research
Source: Reuters
BRIEF-Sage Therapeutics reports top-line results from Phase 3 STATUS trial of brexanolone | Reuters Reuters Staff 1 Min Read Sept 12 (Reuters) - Sage Therapeutics Inc * Sage Therapeutics reports top-line results from Phase 3 STATUS trial of brexanolone in super-refractory status epilepticus * Sage Therapeutics Inc - ?study did not meet primary endpoint * Sage Therapeutics Inc - ?secondary endpoint results were consistent with primary endpoint in study * Sage Therapeutics Inc - ?rate of death was similar in brexanolone and placebo groups in study * Sage Therapeutics Inc - ?rate of adverse events leading to discontinuation of study drug was similar in brexanolone and placebo groups and was low overall * Sage Therapeutics Inc - ?serious adverse events were similar between two treatment groups in trial * Sage Therapeutics - about 37 percent of patients treated with open-label brexanolone after end of double-blind period achieved treatment response? Source text for Eikon: Further company c
Show less
Read more
Impact Snapshot
Event Time:
SAGE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SAGE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SAGE alerts
High impacting Sage Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SAGE
News
- INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Sage Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire
- Sage Therapeutics, Inc. (NASDAQ: SAGE) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.MarketBeat
- Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress [Yahoo! Finance]Yahoo! Finance
- Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business ProgressBusiness Wire
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Sage Therapeutics, Inc. - SAGEGlobeNewswire
SAGE
Earnings
- 4/25/24 - Miss
SAGE
Sec Filings
- 4/25/24 - Form 10-Q
- 4/25/24 - Form 8-K
- 4/24/24 - Form ARS
- SAGE's page on the SEC website